Marsh & McLennan heads into its May 21 Q1 earnings call with the Street broadly constructive but having trimmed expectations — and the stock itself sitting near oversold territory after a rough month.
The analyst picture is the clearest place to start. Most recently, Citigroup upgraded the stock to Buy on May 6, setting a $200 target — a meaningful vote of confidence given the stock is currently at $161.05. That stands against a backdrop of widespread target cuts in April: JPMorgan, Barclays, Morgan Stanley, Wells Fargo, Mizuho, and Keefe Bruyette & Woods all trimmed their numbers, largely as macro uncertainty drove broad-based re-ratings across the insurance broker space. The direction of travel was downward, but most firms held their ratings. The consensus is still a hold, with 6 buys and 13 holds among covering analysts. With the stock now trading well below most price targets — analyst return potential runs to 26% — the Street sees meaningful gap to close.
Short interest is a subdued story here. At 1.24% of the free float, there is simply no meaningful short thesis from the lending market's perspective. The borrow cost has eased to 0.42%, down more than 26% over the past month, and availability remains ample. The ORTEX short score of 29.7 sits in the lower half of its range. This is not a stock that short sellers are pressing into the print.
Options confirm a relaxed pre-earnings tone. The put/call ratio is 0.55, marginally below its 20-day average of 0.57 and well off the 52-week high of 1.50. There is no unusual hedging demand visible in the market. That makes the price action — down 6.8% over the past month and off 13.2% year-to-date — look more like sector rotation and macro re-pricing than a signal of fundamental concern. RSI stands at 38.5, approaching technically oversold territory.
On the insider front, the most notable activity pre-dates this quarter. CEO John Doyle sold $5.7 million of stock in late February and another $3.1 million in March, alongside sales by the CFO and CMO. These were largely compensation-linked disposals, with low significance scores, but the pattern is one of net selling. Against that, institutional ownership remains anchored: Vanguard holds a 9.7% stake and added shares in Q1.
Thursday's print will test whether the underlying business — advisory revenue, risk consulting, and benefits consulting — is holding up against macro headwinds well enough to justify the Street's bullish return potential, or whether the recent target cuts were the first signal of a more sustained re-rating.
See the live data behind this article on ORTEX.
Open MRSH on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
